Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities: 2024-2025

Historic Other Non-Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 2 years, with Sep 2025 value amounting to $2.9 million.

  • Crinetics Pharmaceuticals' Other Non-Current Liabilities rose 466.34% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 466.34%. This contributed to the annual value of $829,000 for FY2024, which is N/A change from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Other Non-Current Liabilities stood at $2.9 million, which was up 23.99% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Other Non-Current Liabilities peaked at $2.9 million during Q3 2025, and registered a low of $202,000 during Q2 2024.
  • For the 2-year period, Crinetics Pharmaceuticals' Other Non-Current Liabilities averaged around $1.4 million, with its median value being $1.3 million (2024).
  • Data for Crinetics Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY surged of 1,055.45% (in 2025) over the last 5 years.
  • Crinetics Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $829,000 in 2024, then surged by 466.34% to $2.9 million in 2025.
  • Its Other Non-Current Liabilities was $2.9 million in Q3 2025, compared to $2.3 million in Q2 2025 and $1.8 million in Q1 2025.